A citation-based method for searching scientific literature

Chris Estes, Homie Razavi, Rohit Loomba, Zobair Younossi, Arun J Sanyal. Hepatology 2018
Times Cited: 875







List of co-cited articles
765 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes.
Zobair M Younossi, Aaron B Koenig, Dinan Abdelatif, Yousef Fazel, Linda Henry, Mark Wymer. Hepatology 2016
42

The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases.
Naga Chalasani, Zobair Younossi, Joel E Lavine, Michael Charlton, Kenneth Cusi, Mary Rinella, Stephen A Harrison, Elizabeth M Brunt, Arun J Sanyal. Hepatology 2018
31


Mechanisms of NAFLD development and therapeutic strategies.
Scott L Friedman, Brent A Neuschwander-Tetri, Mary Rinella, Arun J Sanyal. Nat Med 2018
16

Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016-2030.
Chris Estes, Quentin M Anstee, Maria Teresa Arias-Loste, Heike Bantel, Stefano Bellentani, Joan Caballeria, Massimo Colombo, Antonio Craxi, Javier Crespo, Christopher P Day,[...]. J Hepatol 2018
625
16

Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention.
Zobair Younossi, Quentin M Anstee, Milena Marietti, Timothy Hardy, Linda Henry, Mohammed Eslam, Jacob George, Elisabetta Bugianesi. Nat Rev Gastroenterol Hepatol 2018
14

The economic and clinical burden of nonalcoholic fatty liver disease in the United States and Europe.
Zobair M Younossi, Deirdre Blissett, Robert Blissett, Linda Henry, Maria Stepanova, Youssef Younossi, Andrei Racila, Sharon Hunt, Rachel Beckerman. Hepatology 2016
612
12

Design and validation of a histological scoring system for nonalcoholic fatty liver disease.
David E Kleiner, Elizabeth M Brunt, Mark Van Natta, Cynthia Behling, Melissa J Contos, Oscar W Cummings, Linda D Ferrell, Yao-Chang Liu, Michael S Torbenson, Aynur Unalp-Arida,[...]. Hepatology 2005
11

Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: Systematic review and meta-analysis.
Parambir S Dulai, Siddharth Singh, Janki Patel, Meera Soni, Larry J Prokop, Zobair Younossi, Giada Sebastiani, Mattias Ekstedt, Hannes Hagstrom, Patrik Nasr,[...]. Hepatology 2017
876
11

From NASH to HCC: current concepts and future challenges.
Quentin M Anstee, Helen L Reeves, Elena Kotsiliti, Olivier Govaere, Mathias Heikenwalder. Nat Rev Gastroenterol Hepatol 2019
512
10

The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: A systematic review and meta-analysis.
Zobair M Younossi, Pegah Golabi, Leyla de Avila, James Minhui Paik, Manirath Srishord, Natsu Fukui, Ying Qiu, Leah Burns, Arian Afendy, Fatema Nader. J Hepatol 2019
647
10

Liver Fibrosis, but No Other Histologic Features, Is Associated With Long-term Outcomes of Patients With Nonalcoholic Fatty Liver Disease.
Paul Angulo, David E Kleiner, Sanne Dam-Larsen, Leon A Adams, Einar S Bjornsson, Phunchai Charatcharoenwitthaya, Peter R Mills, Jill C Keach, Heather D Lafferty, Alisha Stahler,[...]. Gastroenterology 2015
10

Global epidemiology of NAFLD-related HCC: trends, predictions, risk factors and prevention.
Daniel Q Huang, Hashem B El-Serag, Rohit Loomba. Nat Rev Gastroenterol Hepatol 2021
353
10

Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up.
Mattias Ekstedt, Hannes Hagström, Patrik Nasr, Mats Fredrikson, Per Stål, Stergios Kechagias, Rolf Hultcrantz. Hepatology 2015
10

MAFLD: A Consensus-Driven Proposed Nomenclature for Metabolic Associated Fatty Liver Disease.
Mohammed Eslam, Arun J Sanyal, Jacob George. Gastroenterology 2020
990
10

Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease.
Stefano Romeo, Julia Kozlitina, Chao Xing, Alexander Pertsemlidis, David Cox, Len A Pennacchio, Eric Boerwinkle, Jonathan C Cohen, Helen H Hobbs. Nat Genet 2008
9

Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial.
Brent A Neuschwander-Tetri, Rohit Loomba, Arun J Sanyal, Joel E Lavine, Mark L Van Natta, Manal F Abdelmalek, Naga Chalasani, Srinivasan Dasarathy, Anna Mae Diehl, Bilal Hameed,[...]. Lancet 2015
9


A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement.
Mohammed Eslam, Philip N Newsome, Shiv K Sarin, Quentin M Anstee, Giovanni Targher, Manuel Romero-Gomez, Shira Zelber-Sagi, Vincent Wai-Sun Wong, Jean-François Dufour, Jörn M Schattenberg,[...]. J Hepatol 2020
9

Nonalcoholic Steatohepatitis: A Review.
Adam C Sheka, Oyedele Adeyi, Julie Thompson, Bilal Hameed, Peter A Crawford, Sayeed Ikramuddin. JAMA 2020
360
9

NASH limits anti-tumour surveillance in immunotherapy-treated HCC.
Dominik Pfister, Nicolás Gonzalo Núñez, Roser Pinyol, Olivier Govaere, Matthias Pinter, Marta Szydlowska, Revant Gupta, Mengjie Qiu, Aleksandra Deczkowska, Assaf Weiner,[...]. Nature 2021
280
9

The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD).
Elena Buzzetti, Massimo Pinzani, Emmanuel A Tsochatzis. Metabolism 2016
9


Fibrosis Severity as a Determinant of Cause-Specific Mortality in Patients With Advanced Nonalcoholic Fatty Liver Disease: A Multi-National Cohort Study.
Eduardo Vilar-Gomez, Luis Calzadilla-Bertot, Vincent Wai-Sun Wong, Marlen Castellanos, Rocio Aller-de la Fuente, Mayada Metwally, Mohammed Eslam, Licet Gonzalez-Fabian, María Alvarez-Quiñones Sanz, Antonio Felix Conde-Martin,[...]. Gastroenterology 2018
360
8

Hypertension, diabetes, atherosclerosis and NASH: Cause or consequence?
Amedeo Lonardo, Fabio Nascimbeni, Alessandro Mantovani, Giovanni Targher. J Hepatol 2018
324
8

Weight Loss Through Lifestyle Modification Significantly Reduces Features of Nonalcoholic Steatohepatitis.
Eduardo Vilar-Gomez, Yadina Martinez-Perez, Luis Calzadilla-Bertot, Ana Torres-Gonzalez, Bienvenido Gra-Oramas, Licet Gonzalez-Fabian, Scott L Friedman, Moises Diago, Manuel Romero-Gomez. Gastroenterology 2015
7

The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD.
Paul Angulo, Jason M Hui, Giulio Marchesini, Ellisabetta Bugianesi, Jacob George, Geoffrey C Farrell, Felicity Enders, Sushma Saksena, Alastair D Burt, John P Bida,[...]. Hepatology 2007
7

A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis.
Philip N Newsome, Kristine Buchholtz, Kenneth Cusi, Martin Linder, Takeshi Okanoue, Vlad Ratziu, Arun J Sanyal, Anne-Sophie Sejling, Stephen A Harrison. N Engl J Med 2021
357
7

Hepatocellular Carcinoma in the Absence of Cirrhosis in United States Veterans is Associated With Nonalcoholic Fatty Liver Disease.
Sahil Mittal, Hashem B El-Serag, Yvonne H Sada, Fasiha Kanwal, Zhigang Duan, Sarah Temple, Sarah B May, Jennifer R Kramer, Peter A Richardson, Jessica A Davila. Clin Gastroenterol Hepatol 2016
342
7

Non-alcoholic fatty liver disease and risk of incident cardiovascular disease: A meta-analysis.
Giovanni Targher, Christopher D Byrne, Amedeo Lonardo, Giacomo Zoppini, Corrado Barbui. J Hepatol 2016
664
7

Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection.
Richard K Sterling, Eduardo Lissen, Nathan Clumeck, Ricard Sola, Mendes Cassia Correa, Julio Montaner, Mark S Sulkowski, Francesca J Torriani, Doug T Dieterich, David L Thomas,[...]. Hepatology 2006
7

The incidence and risk factors of hepatocellular carcinoma in patients with nonalcoholic steatohepatitis.
Mustafa S Ascha, Ibrahim A Hanouneh, Rocio Lopez, Tarek Abu-Rajab Tamimi, Ariel F Feldstein, Nizar N Zein. Hepatology 2010
834
7

Global Perspectives on Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis.
Zobair Younossi, Frank Tacke, Marco Arrese, Barjesh Chander Sharma, Ibrahim Mostafa, Elisabetta Bugianesi, Vincent Wai-Sun Wong, Yusuf Yilmaz, Jacob George, Jiangao Fan,[...]. Hepatology 2019
698
7

Cause, Pathogenesis, and Treatment of Nonalcoholic Steatohepatitis.
Anna M Diehl, Christopher Day. N Engl J Med 2017
558
7

Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study.
Matthew James Armstrong, Piers Gaunt, Guruprasad P Aithal, Darren Barton, Diana Hull, Richard Parker, Jonathan M Hazlehurst, Kathy Guo, George Abouda, Mark A Aldersley,[...]. Lancet 2016
944
6


Burden of Illness and Economic Model for Patients With Nonalcoholic Steatohepatitis in the United States.
Zobair M Younossi, Radhika Tampi, Massoom Priyadarshini, Fatema Nader, Issah M Younossi, Andrei Racila. Hepatology 2019
86
6

Triggering and resolution of inflammation in NASH.
Susanne Schuster, Daniel Cabrera, Marco Arrese, Ariel E Feldstein. Nat Rev Gastroenterol Hepatol 2018
319
6

Risks and clinical predictors of cirrhosis and hepatocellular carcinoma diagnoses in adults with diagnosed NAFLD: real-world study of 18 million patients in four European cohorts.
Myriam Alexander, A Katrina Loomis, Johan van der Lei, Talita Duarte-Salles, Daniel Prieto-Alhambra, David Ansell, Alessandro Pasqua, Francesco Lapi, Peter Rijnbeek, Mees Mosseveld,[...]. BMC Med 2019
111
6

CONTROL: A randomized phase 2 study of obeticholic acid and atorvastatin on lipoproteins in nonalcoholic steatohepatitis patients.
Paul J Pockros, Michael Fuchs, Bradley Freilich, Eugene Schiff, Anita Kohli, Eric J Lawitz, Paul A Hellstern, Janet Owens-Grillo, Courtney Van Biene, Reshma Shringarpure,[...]. Liver Int 2019
73
8

Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial.
Zobair M Younossi, Vlad Ratziu, Rohit Loomba, Mary Rinella, Quentin M Anstee, Zachary Goodman, Pierre Bedossa, Andreas Geier, Susanne Beckebaum, Philip N Newsome,[...]. Lancet 2019
488
6

Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease.
Kerry L Donnelly, Coleman I Smith, Sarah J Schwarzenberg, Jose Jessurun, Mark D Boldt, Elizabeth J Parks. J Clin Invest 2005
6

Epidemiology of chronic liver diseases in the USA in the past three decades.
Zobair M Younossi, Maria Stepanova, Youssef Younossi, Pegah Golabi, Alita Mishra, Nila Rafiq, Linda Henry. Gut 2020
162
6

Nonalcoholic Steatohepatitis Is the Fastest Growing Cause of Hepatocellular Carcinoma in Liver Transplant Candidates.
Zobair Younossi, Maria Stepanova, Janus P Ong, Ira M Jacobson, Elisabetta Bugianesi, Ajay Duseja, Yuichiro Eguchi, Vincent W Wong, Francesco Negro, Yusuf Yilmaz,[...]. Clin Gastroenterol Hepatol 2019
372
6

Association of nonalcoholic fatty liver disease (NAFLD) with hepatocellular carcinoma (HCC) in the United States from 2004 to 2009.
Zobair M Younossi, Munkhzul Otgonsuren, Linda Henry, Chapy Venkatesan, Alita Mishra, Madeline Erario, Sharon Hunt. Hepatology 2015
459
6

The Burden of Primary Liver Cancer and Underlying Etiologies From 1990 to 2015 at the Global, Regional, and National Level: Results From the Global Burden of Disease Study 2015.
Tomi Akinyemiju, Semaw Abera, Muktar Ahmed, Noore Alam, Mulubirhan Assefa Alemayohu, Christine Allen, Rajaa Al-Raddadi, Nelson Alvis-Guzman, Yaw Amoako, Al Artaman,[...]. JAMA Oncol 2017
962
6

NAFLD: a multisystem disease.
Christopher D Byrne, Giovanni Targher. J Hepatol 2015
5

Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis.
Arun J Sanyal, Naga Chalasani, Kris V Kowdley, Arthur McCullough, Anna Mae Diehl, Nathan M Bass, Brent A Neuschwander-Tetri, Joel E Lavine, James Tonascia, Aynur Unalp,[...]. N Engl J Med 2010
5


The role of macrophages in nonalcoholic fatty liver disease and nonalcoholic steatohepatitis.
Konstantin Kazankov, Simon Mark Dahl Jørgensen, Karen Louise Thomsen, Holger Jon Møller, Hendrik Vilstrup, Jacob George, Detlef Schuppan, Henning Grønbæk. Nat Rev Gastroenterol Hepatol 2019
333
5


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.